Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 3/2019

01-03-2019 | Short Communication

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

Authors: Lucien Marchand, Sophie Reffet, Stéphane Dalle, Emmanuel Disse, Julien Vouillarmet, Christine Cugnet-Anceau, Charles Thivolet

Published in: Acta Diabetologica | Issue 3/2019

Login to get access

Excerpt

We read with interest the paper by Tassone et al., describing difficulties in achieving a good metabolic control and high glucose variability in a subject who presented nivolumab-induced fulminant diabetes (FD) [1]. These issues were not detailed in recent reviews and the large case series of diabetes induced by immune checkpoint inhibitors. …
Literature
1.
2.
Monnier L, Colette C, Wojtusciszyn A et al (2017) Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 40(7):832–838 (PubMed PMID: 28039172) CrossRefPubMed
3.
Marchand L, Reffet S, Vouillarmet J, Cugnet-Anceau C, Disse E, Thivolet C (2018) The 36% coefficient of variation for glucose proposed for separating stable and labile diabetes is clinically relevant: a continuous glucose monitoring-based study in a large population of type 1 diabetes patients. Diabetes Metab. https://​doi.​org/​10.​1016/​j.​diabet.​2018.​05.​009 (PubMed PMID: 29910090) CrossRefPubMed
4.
5.
Marchand L, Paulus V, Fabien N et al (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 12(11):e182–e184 (PubMed PMID: 29074210) CrossRefPubMed
Metadata
Title
Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
Authors
Lucien Marchand
Sophie Reffet
Stéphane Dalle
Emmanuel Disse
Julien Vouillarmet
Christine Cugnet-Anceau
Charles Thivolet
Publication date
01-03-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1262-4

Other articles of this Issue 3/2019

Acta Diabetologica 3/2019 Go to the issue

Original Article

Transient neonatal diabetes mellitus and hypomethylation at additional imprinted loci: novel ZFP57 mutation and review on the literature

Short Communication

Comparison of correlations of equation-derived body fat percentage and body mass index with carotid intima-media thickness

Original Article

Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis

Original Article

Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

Letter to the Editor

Glucose variability in PD-1 inhibitors-induced diabetes mellitus

Original Article

Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits